Advanced

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Garderet, Laurent; Ziagkos, Dimitris; van Biezen, Anja; Iacobelli, Simona; Finke, Jürgen; Maertens, Johan; Volin, Liisa; Ljungman, Per; Chevallier, Patrice and Passweg, Jakob, et al. (2018) In Biology of Blood and Marrow Transplantation
Abstract

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4... (More)

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Allogeneic stem cell transplantation, Del (5q), MDS
in
Biology of Blood and Marrow Transplantation
publisher
Elsevier
external identifiers
  • scopus:85039787955
ISSN
1083-8791
DOI
language
English
LU publication?
no
id
56621485-6b50-4480-bb76-9ebd8bd99ec0
date added to LUP
2018-01-22 11:57:21
date last changed
2018-05-29 12:06:29
@article{56621485-6b50-4480-bb76-9ebd8bd99ec0,
  abstract     = {<p>The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P &lt; .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.</p>},
  author       = {Garderet, Laurent and Ziagkos, Dimitris and van Biezen, Anja and Iacobelli, Simona and Finke, Jürgen and Maertens, Johan and Volin, Liisa and Ljungman, Per and Chevallier, Patrice and Passweg, Jakob and Schaap, Nicolaas and Beelen, Dietrich and Nagler, Arnon and Blaise, Didier and Poiré, Xavier and Yakoub-Agha, Ibrahim and Lenhoff, Stig and Craddock, Charles and Schots, Rik and Rambaldi, Alessandro and Sanz, Jaime and Jindra, Pavel and Mufti, Ghulam J. and Robin, Marie and Kröger, Nicolaus},
  issn         = {1083-8791},
  keyword      = {Allogeneic stem cell transplantation,Del (5q),MDS},
  language     = {eng},
  publisher    = {Elsevier},
  series       = {Biology of Blood and Marrow Transplantation},
  title        = {Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion},
  url          = {http://dx.doi.org/},
  year         = {2018},
}